Top Markets
Coin of the day
BioVaxys Technology Corp. BioVaxys Technology Corp.

BioVaxys Technology Corp.

BIOV
株式のランク #37710
BioVaxys Technology Corp. is a clinical-stage biotechnology company... BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.
株価
$0.05137558
最終同期: 2026-06-01
時価総額
$1.50M
変化(1日)
0.00%
変化(1年)
-71.60%
CA
取引 BioVaxys Technology Corp. (BIOV)

カテゴリー

BioVaxys Technology Corp.(BIOV)の配当利回りの履歴
BioVaxys Technology Corp.(銘柄コード: BIOV)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
BioVaxys Technology Corp.(BIOV)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)